Biogen Idec Gearing Up For Major Launches Seeking Alpha Biogen also benefits from the fact that two of its potential competitors - daclizumab and ocrelizumab - are partnered programs with Abbott (ABT) and Roche (RHHBY.PK), respectively, and Biogen controls the development of the first. |
